Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Elisabeth Rosenthal has called for the FDA to enhance its efforts in regulating misleading claims related to health treatments, as highlighted in her recent op-ed. The piece has garnered mixed reactions, with some experts, including Alec Gaffney, expressing concern over inaccuracies in her portrayal of FDA regulations regarding drug advertisements. Meanwhile, in a related development, the SEC has approved stricter enforcement measures by the PCAOB, which will increase scrutiny on accounting firms, reflecting a growing demand for accountability in financial practices.
While opinions on the need for tougher auditor liability standards are split along party lines, one thing is certain- accounting firms are about to face even more pressure with the SEC's approval of stricter PCAOB enforcement. Our Miriam Robin explains. https://t.co/iyD2OlXyyZ
Dancing, biking, singing patients? The FDA needs to do more to crack down on misleading claims, @RosenthalHealth writes https://t.co/gYgKjkODlX
There are few voices on health policy topics I respect more than Elisabeth Rosenthal, whose writing has long been a staple of of my daily reading and bookshelf, but jeez does this op-ed get a lot of basic stuff wrong about how the FDA actually regulates drug ads. https://t.co/iamEV6asQr